PDB Short entry for 1JOH HEADER ANTIBIOTIC 11-OCT-97 1JOH TITLE THE STRUCTURE OF ANTIAMOEBIN I, A MEMBRANE-ACTIVE PEPTIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: ANTIAMOEBIN I; COMPND 3 CHAIN: A, B SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: EMERICELLOPSIS; SOURCE 3 ORGANISM_TAXID: 45244 KEYWDS ANTIAMOEBIN I, PEPTAIBOL, ANTIBACTERIAL, ANTIFUNGAL, ANTIBIOTIC EXPDTA X-RAY DIFFRACTION AUTHOR C.F.SNOOK,B.A.WALLACE REVDAT 6 03-APR-24 1JOH 1 LINK REVDAT 5 04-MAR-20 1JOH 1 REMARK HETSYN LINK REVDAT 4 27-JUL-11 1JOH 1 REMARK REVDAT 3 13-JUL-11 1JOH 1 VERSN REVDAT 2 24-FEB-09 1JOH 1 VERSN REVDAT 1 20-JAN-99 1JOH 0 JRNL AUTH C.F.SNOOK,G.A.WOOLLEY,G.OLIVA,V.PATTABHI,S.F.WOOD, JRNL AUTH 2 T.L.BLUNDELL,B.A.WALLACE JRNL TITL THE STRUCTURE AND FUNCTION OF ANTIAMOEBIN I, A PROLINE-RICH JRNL TITL 2 MEMBRANE-ACTIVE POLYPEPTIDE. JRNL REF STRUCTURE V. 6 783 1998 JRNL REFN ISSN 0969-2126 JRNL PMID 9655831 JRNL DOI 10.1016/S0969-2126(98)00079-3 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH C.F.SNOOK,B.A.WALLACE REMARK 1 TITL THE MOLECULAR-REPLACEMENT SOLUTION OF AN INTERMEDIATE-SIZED REMARK 1 TITL 2 HELICAL POLYPEPTIDE, ANTIAMOEBIN I. REMARK 1 REF ACTA CRYSTALLOGR.,SECT.D V. 55 1539 1999 REMARK 1 REFN ISSN 0907-4449 REMARK 1 PMID 10489449 REMARK 1 DOI 10.1107/S0907444999007921 REMARK 1 REFERENCE 2 REMARK 1 AUTH C.F.SNOOK REMARK 1 TITL THE STRUCTURE AND FUNCTION OF ANTIAMOEBIN I, A REMARK 1 TITL 2 MEMBRANE-ACTIVE PEPTIDE REMARK 1 REF THESIS, UNIVERSITY OF LONDON 1997 REMARK 1 PUBL LONDON : UNIVERSITY OF LONDON (THESIS) REMARK 1 REFERENCE 3 REMARK 1 AUTH G.OLIVA REMARK 1 TITL MOLECULAR REDUNDANCY AND PROTEIN CRYSTALLOGRAPHY : X-RAY REMARK 1 TITL 2 STRUCTURE ANALYSIS OF ANTIAMOEBIN I, BOVINE PANCREATIC REMARK 1 TITL 3 POLYPEPTIDE AND HUMAN SERUM AMYLOID P COMPONENT REMARK 1 REF THESIS, UNIVERSITY OF LONDON 1988 REMARK 1 PUBL LONDON : UNIVERSITY OF LONDON (THESIS) REMARK 2 REMARK 2 RESOLUTION. 1.40 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-93 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.40 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 25.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 95.4 REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.156 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.156 REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 4359 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.136 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE (F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 3567 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 238 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 30 REMARK 3 SOLVENT ATOMS : 0 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 268.00 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : NULL REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : NULL REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 1074 REMARK 3 NUMBER OF RESTRAINTS : 982 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.036 REMARK 3 ANGLE DISTANCES (A) : 3.152 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.000 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.000 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.000 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.016 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.005 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.022 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.065 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: HETATM DATA FROM CCSD REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REFINEMENT STARTED USING 10.0 TO 2.5A REMARK 3 AND DATA CUT-OFF AT 2 SIGMA IN X-PLOR. HIGH RESOLUTION LIMIT REMARK 3 INCREASED TO 2.0A, LOW RESOLUTION DECREASED TO 25.0A AND DATA REMARK 3 CUT-OFF DECREASED TO 0.0 SIGMA AT 2.0A RESOLUTION. RESOLUTION REMARK 3 INCREASED FROM 2.0A TO 1.4A WITH ALL DATA USING SHELXL-93. REMARK 3 REFINEMENT CEASED AFTER RESIDUES 1 TO 5 IN B-CHAIN IDENTIFIED AS REMARK 3 DISORDERED IN DENSITY. REMARK 4 REMARK 4 1JOH COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000174352. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 1986 REMARK 200 TEMPERATURE (KELVIN) : 293 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : SEALED TUBE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NI FILTER REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : DIFFRACTOMETER REMARK 200 DETECTOR MANUFACTURER : HILGER-WATTS REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 6715 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.200 REMARK 200 RESOLUTION RANGE LOW (A) : 25.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 93.7 REMARK 200 DATA REDUNDANCY : 1.000 REMARK 200 R MERGE (I) : 0.01200 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 10.5000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: SHELXL-93 REMARK 200 STARTING MODEL: RESIDUES 6 - 16 OF LEU1-ZERVAMICIN WITH ALL NON REMARK 200 -EQUIVALENT SIDE-CHAINS TRIMMED TO ALA. REMARK 200 REMARK 200 REMARK: USED NORMALISED STRUCTURE FACTORS REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 28.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.71 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 ANTIAMOEBIN I IS LINEAR PEPTIDE, A MEMBER OF THE PEPTAIBOL REMARK 400 FAMILY OF MEMBRANE CHANNEL FORMING PEPTIDES. REMARK 400 HERE, ANTIAMOEBIN I IS REPRESENTED BY THE SEQUENCE (SEQRES) REMARK 400 REMARK 400 THE ANTIAMOEBIN 1 IS PEPTAIBOL, A MEMBER OF ANTIBIOTIC CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: ANTIAMOEBIN 1 REMARK 400 CHAIN: A, B REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: ANTIAMOEBIN I IS A HEXADECAMERIC HELICAL PEPTIDE. REMARK 400 THE N-TERM IS ACETYLATED (RESIDUE 0) REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 CB PHL B 16 O MOH B 23 0.81 REMARK 500 CA PHL B 16 O MOH B 23 2.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O MOH A 27 O MOH B 28 1554 1.99 REMARK 500 C PHL A 16 C MOH A 18 1556 2.10 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 AIB B 2 C - N - CA ANGL. DEV. = 20.3 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 AIB B 2 -53.93 -137.07 REMARK 500 REMARK 500 REMARK: NULL REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 MOH A 23 REMARK 610 MOH A 24 REMARK 610 MOH A 25 REMARK 610 MOH A 26 REMARK 610 MOH A 28 REMARK 610 MOH B 20 REMARK 610 MOH B 21 REMARK 610 MOH B 22 REMARK 610 MOH B 24 REMARK 610 MOH B 25 REMARK 610 MOH B 26 REMARK 610 MOH B 27 REMARK 610 MOH B 28 REMARK 610 MOH B 29 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN A OF ANTIAMOEBIN I REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN B OF ANTIAMOEBIN I REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1M24 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PEPTAIBOL TRICHOTOXIN_A50E REMARK 900 RELATED ID: 1R9U RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE PEPTAIBOL ZERVAMICIN IIB IN METHANOL REMARK 900 RELATED ID: 1DLZ RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE PEPTIABOL ZERVAMICIN IIB REMARK 900 RELATED ID: 1IH9 RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE PEPTAIBOL ZERVAMICIN IIB BOUND TO DPC REMARK 900 MICELLES REMARK 900 RELATED ID: 1GQ0 RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE PEPTAIBOL ANTIAMOEBIN I REMARK 900 RELATED ID: 1AMT RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PEPTAIBOL ALAMETHICIN REMARK 900 RELATED ID: 1EE7 RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE PEPTAIBOL CHRYSOSPERMIN C BOUND TO DPC REMARK 900 MICELLES REMARK 900 RELATED ID: 1OB7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PEPTAIBOL CEPHAIBOL C REMARK 900 RELATED ID: 1OB6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PEPTAIBOL CEPHAIBOL B REMARK 900 RELATED ID: 1OB4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PEPTAIBOL CEPHAIBOL A DBREF 1JOH A 0 16 NOR NOR00945 NOR00945 0 16 DBREF 1JOH B 0 16 NOR NOR00945 NOR00945 0 16 SEQRES 1 A 17 ACE PHE AIB AIB AIB DIV GLY LEU AIB AIB HYP GLN DIV SEQRES 2 A 17 HYP AIB PRO PHL SEQRES 1 B 17 ACE PHE AIB AIB AIB DIV GLY LEU AIB AIB HYP GLN DIV SEQRES 2 B 17 HYP AIB PRO PHL HET ACE A 0 3 HET AIB A 2 6 HET AIB A 3 6 HET AIB A 4 6 HET DIV A 5 7 HET AIB A 8 6 HET AIB A 9 6 HET HYP A 10 8 HET DIV A 12 7 HET HYP A 13 8 HET AIB A 14 6 HET PHL A 16 11 HET ACE B 0 3 HET AIB B 2 6 HET AIB B 3 6 HET AIB B 4 6 HET DIV B 5 7 HET AIB B 8 6 HET AIB B 9 6 HET HYP B 10 8 HET DIV B 12 7 HET HYP B 13 8 HET AIB B 14 6 HET PHL B 16 11 HET MOH A 18 2 HET MOH A 19 2 HET MOH A 20 2 HET MOH A 21 2 HET MOH A 22 2 HET MOH A 23 1 HET MOH A 24 1 HET MOH A 25 1 HET MOH A 26 1 HET MOH A 27 1 HET MOH A 28 1 HET MOH B 18 2 HET MOH B 19 2 HET MOH B 20 1 HET MOH B 21 1 HET MOH B 22 1 HET MOH B 23 1 HET MOH B 24 1 HET MOH B 25 1 HET MOH B 26 1 HET MOH B 27 1 HET MOH B 28 1 HET MOH B 29 1 HETNAM ACE ACETYL GROUP HETNAM AIB ALPHA-AMINOISOBUTYRIC ACID HETNAM DIV D-ISOVALINE HETNAM HYP 4-HYDROXYPROLINE HETNAM PHL L-PHENYLALANINOL HETNAM MOH METHANOL HETSYN HYP HYDROXYPROLINE HETSYN PHL BOUND FORM OF PHENYLALANINAL FORMUL 1 ACE 2(C2 H4 O) FORMUL 1 AIB 12(C4 H9 N O2) FORMUL 1 DIV 4(C5 H11 N O2) FORMUL 1 HYP 4(C5 H9 N O3) FORMUL 1 PHL 2(C9 H13 N O) FORMUL 3 MOH 23(C H4 O) HELIX 1 1 PHE A 1 HYP A 10 1 10 HELIX 2 2 AIB B 2 HYP B 10 1 9 LINK C ACE A 0 N PHE A 1 1555 1555 1.34 LINK C PHE A 1 N AIB A 2 1555 1555 1.32 LINK C AIB A 2 N AIB A 3 1555 1555 1.33 LINK C AIB A 3 N AIB A 4 1555 1555 1.31 LINK C AIB A 4 N DIV A 5 1555 1555 1.34 LINK C DIV A 5 N GLY A 6 1555 1555 1.33 LINK C LEU A 7 N AIB A 8 1555 1555 1.32 LINK C AIB A 8 N AIB A 9 1555 1555 1.34 LINK C AIB A 9 N HYP A 10 1555 1555 1.32 LINK C HYP A 10 N GLN A 11 1555 1555 1.31 LINK C GLN A 11 N DIV A 12 1555 1555 1.34 LINK C DIV A 12 N HYP A 13 1555 1555 1.31 LINK C HYP A 13 N AIB A 14 1555 1555 1.32 LINK C AIB A 14 N PRO A 15 1555 1555 1.31 LINK C PRO A 15 N PHL A 16 1555 1555 1.32 LINK O PHL A 16 C MOH A 18 1554 1555 1.76 LINK O PHL A 16 C MOH A 18 1555 1556 1.76 LINK O MOH A 27 C MOH B 19 1555 1555 1.84 LINK C ACE B 0 N PHE B 1 1555 1555 1.33 LINK C PHE B 1 N AIB B 2 1555 1555 1.29 LINK C AIB B 2 N AIB B 3 1555 1555 1.32 LINK C AIB B 3 N AIB B 4 1555 1555 1.36 LINK C AIB B 4 N DIV B 5 1555 1555 1.32 LINK C DIV B 5 N GLY B 6 1555 1555 1.35 LINK C LEU B 7 N AIB B 8 1555 1555 1.34 LINK C AIB B 8 N AIB B 9 1555 1555 1.35 LINK C AIB B 9 N HYP B 10 1555 1555 1.32 LINK C HYP B 10 N GLN B 11 1555 1555 1.32 LINK C GLN B 11 N DIV B 12 1555 1555 1.32 LINK C DIV B 12 N HYP B 13 1555 1555 1.35 LINK C HYP B 13 N AIB B 14 1555 1555 1.31 LINK C AIB B 14 N PRO B 15 1555 1555 1.30 LINK C PRO B 15 N PHL B 16 1555 1555 1.31 LINK CG PHL B 16 O MOH B 23 1555 1555 1.65 SITE 1 AC1 7 PHE B 1 GLY B 6 LEU B 7 AIB B 9 SITE 2 AC1 7 HYP B 10 GLN B 11 PHL B 16 SITE 1 AC2 8 DIV A 5 GLY A 6 LEU A 7 AIB A 8 SITE 2 AC2 8 AIB A 9 HYP A 10 GLN A 11 PHL A 16 CRYST1 26.530 28.820 9.060 88.90 96.64 123.85 P 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.037693 0.025281 0.005782 0.00000 SCALE2 0.000000 0.041780 0.002293 0.00000 SCALE3 0.000000 0.000000 0.111288 0.00000 MTRIX1 1 0.000000 1.000000 0.000000 0.00000 1 MTRIX2 1 1.000000 0.000000 0.000000 0.00000 1 MTRIX3 1 0.000000 0.000000 -1.000000 115.46000 1 HETATM 1 C ACE A 0 2.849 -3.303 6.755 1.00 8.83 C HETATM 2 O ACE A 0 3.769 -3.853 5.982 1.00 22.92 O HETATM 3 CH3 ACE A 0 2.419 -2.235 6.503 1.00 4.21 C